Clinical pharmacists as multidisciplinary health care providers in the management of CKD: A joint opinion by the nephrology and ambulatory care practice and research networks of the american College of Clinical Pharmacy

American Journal of Kidney Diseases

Volumn 45, Issue 6, 2005, Pages 1105-1118

  Joy, Melanie S ^a   DeHart, Renee M ^b   Gilmartin, Cheryl ^c   Hachey, David M ^d   Hudson, Joanna Q ^e   Pruchnicki, Maria ^f   Dumo, Peter ^g   Grabe, Darren W ^h   Saseen, Joseph ⁱ   Zillich, Alan J ^j  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b SAMFORD UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d IDAHO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g HARPER UNIVERSITY HOSPITAL   (United States)

^h ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j PURDUE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT ERYTHROPOIETIN;

AMBULATORY CARE; ANEMIA; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DIALYSIS; DOSIMETRY; DRUG INDUSTRY; HEALTH CARE; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH PRACTITIONER; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL RESEARCH; METABOLIC BONE DISEASE; MONITORING; NEPHROLOGY; OUTCOMES RESEARCH; PATIENT CARE; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PHARMACIST; PHARMACOLOGICAL PARAMETERS; PHARMACY; PRACTICE GUIDELINE; PRESCRIPTION; PREVALENCE; REVIEW; SOCIAL WORK; TRAINING;

EID: 20444381330     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2005.02.027     Document Type: Editorial

References (146)

1. Consensus Development Conference Panel Morbidity and mortality of renal dialysis An NIH consensus conference statement Ann Intern Med 121 1994 62 70
2. US Department of Health and Human Services Healthy People 2000 1990 US Government Printing Office Washington, DC
3. US Department of Health and Human Services Healthy People 2010 2000 US Government Printing Office
4. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease Evaluation, classification, and stratification Am J Kidney Dis 39 suppl 1 2002 S1 S266
5. A.J. Collins, B. Kasiske, C. Herzog Excerpts from the United States Renal Data System 2003 Annual Data Report Atlas of end-stage renal disease in the United States Am J Kidney Dis 42 2003 A5 A7
6. A.R. Nissenson, A.J. Collins, J. Hurley Opportunities for improving the care of patients with chronic renal insufficiency Current practice patterns J Am Soc Nephrol 12 2001 1713 1720
7. B.J. Pereira Optimization of pre-ESRD care The key to improved dialysis outcomes Kidney Int 57 2000 351 365
8. C.A. Jones, G.M. McQuillan, J.W. Kusek Serum creatinine levels in the US population Third National Health and Nutrition Examination Survey Am J Kidney Dis 32 1998 992 999
9. G. Eknoyan, A.S. Levey, N.W. Levin, W.F. Keane The national epidemic of chronic kidney disease. What we know and what we can do Postgrad Med 110 2001 23 29
10. B.J. Pereira Introduction New perspectives in chronic renal insufficiency Am J Kidney Dis 36 suppl 3 2000 S1 S3
11. E.G. Neilson, A.R. Hull, J.B. Wish The ad hoc committee report on estimating the future workforce and training requirements for nephrology. The Ad Hoc Committee on Nephrology Manpower Needs J Am Soc Nephrol 8 suppl 9 1997 S1 S4
12. Ad Hoc Committee on Nephrology Manpower Needs Estimating workforce and training requirements for nephrologists through the year 2010 J Am Soc Nephrol 8 suppl 9 1997 S9 S13 i-xxii, S11-S32 passim
13. K.S. Yarnall, K.I. Pollak, T. Ostbye, K.M. Krause, J.L. Michener Primary care Is there enough time for prevention? Am J Public Health 93 2003 635 641
14. A.M. Bernard, L. Anderson, C.B. Cook, L.S. Phillips What do internal medicine residents need to enhance their diabetes care? Diabetes Care 22 1999 661 666
15. G.T. Obrador, R. Ruthazer, P. Arora, A.T. Kausz, B.J. Pereira Prevalence of and factors associated with suboptimal care before initiation of dialysis in the United States J Am Soc Nephrol 10 1999 1793 1800
16. W.F. Owen Jr Patterns of care for patients with chronic kidney disease in the United States Dying for improvement J Am Soc Nephrol 14 suppl 2 2003 S76 S80
17. A.J. Collins, S. Fishbane, R. London, B.G. Pereira, I. Zawadski Chronic kidney disease Stating the managed care case for early treatment Am J Managed Care 8 suppl 2002 S114 S120
18. G.T. Obrador, B.J. Pereira Early referral to the nephrologist and timely initiation of renal replacement therapy A paradigm shift in the management of patients with chronic renal failure Am J Kidney Dis 31 1998 398 417
19. A.T. Kausz, S.S. Khan, R. Abichandani Management of patients with chronic renal insufficiency in the northeastern United States J Am Soc Nephrol 12 2001 1501 1507
20. A. Besarab, R.P. Ross, T.J. Nasca The use of recombinant human erythropoietin in predialysis patients Curr Opin Nephrol Hypertens 4 1995 155 161
21. D. Tsakiris Morbidity and mortality reduction associated with the use of erythropoietin Nephron 85 suppl 1 2000 S2 S8
22. W.M. McClellan, D.F. Knight, H. Karp, W.W. Brown Early detection and treatment of renal disease in hospitalized diabetic and hypertensive patients Important differences between practice and published guidelines Am J Kidney Dis 29 1997 368 375
23. L. Kissmeyer, C. Kong, J. Cohen Community nephrology Audit of screening for renal insufficiency in a high risk population Nephrol Dial Transplant 14 1999 2150 2155
24. S.K. Kraft, E.N. Lazaridis, C. Qiu, C.M. Clark Jr, D.G. Marrero Screening and treatment of diabetic nephropathy by primary care physicians J Gen Intern Med 14 1999 88 97
25. K.L. Miller, I.B. Hirsch Physicians' practices in screening for the development of diabetic nephropathy and the use of glycosylated hemoglobin levels Diabetes Care 17 1994 1495 1497
26. E.A. McGlynn, S.M. Asch, J. Adams The quality of health care delivered to adults in the United States N Engl J Med 348 2003 2635 2645
27. A.V. Kshirsagar, M.S. Joy, S.L. Hogan, R.J. Falk, R.E. Colindres Effect of ACE inhibitors in diabetic and nondiabetic chronic renal disease A systematic overview of randomized placebo-controlled trials Am J Kidney Dis 35 2000 695 707
28. R.A. Hamilton, M.P. Kane, J. Demers Angiotensin-converting enzyme inhibitors and type 2 diabetic nephropathy A meta-analysis Pharmacotherapy 23 2003 909 915
29. A.R. Nissenson, B.J. Pereira, A.J. Collins, E.P. Steinberg Prevalence and characteristics of individuals with chronic kidney disease in a large health maintenance organization Am J Kidney Dis 37 2001 1177 1183
30. G.T. Obrador, T. Roberts, W.L. St Peter Trends in anemia at initiation of dialysis in the United States Kidney Int 60 2001 1875 1884
31. B.J. Pereira Overcoming barriers to the early detection and treatment of chronic kidney disease and improving outcomes for end-stage renal disease Am J Managed Care 8 suppl 2002 S122 S135
32. P. Arora, G.T. Obrador, R. Ruthazer Prevalence, predictors, and consequences of late nephrology referral at a tertiary care center J Am Soc Nephrol 10 1999 1281 1286
33. J. Avorn, R.L. Bohn, E. Levy Nephrologist care and mortality in patients with chronic renal insufficiency Arch Intern Med 162 2002 2002 2006
34. C. Mosley Coordination of care in disease management Opportunities and financial issues Semin Dial 13 2000 346 350
35. A.R. Hull The legislative and regulatory process in the end-stage renal disease (ESRD) program, 1973 through 1997 Semin Nephrol 17 1997 160 169
36. A.R. Nissenson, J.M. Lazarus, S.M. Lindenfeld, R.M. Hakim, S.J. Bander The current and future state of the ESRD program A provider roundtable Semin Nephrol 20 2000 543 555
37. W.L. St Peter, A.C. Schoolwerth, T. McGowan, W.M. McClellan Chronic kidney disease Issues and establishing programs and clinics for improved patient outcomes Am J Kidney Dis 41 2003 903 924
38. S. Sankarasubbaiyan, J.L. Holley An analysis of the increased demands placed on dialysis health care team members by functionally dependent hemodialysis patients Am J Kidney Dis 35 2000 1061 1067
39. D.W. Grabe, C.L. Low, G.R. Bailie, G. Eisele Evaluation of drug-related problems in an outpatient hemodialysis unit and the impact of a clinical pharmacist Clin Nephrol 47 1997 117 121
40. H.J. Manley, M.L. McClaran, D.K. Overbay Factors associated with medication-related problems in ambulatory hemodialysis patients Am J Kidney Dis 41 2003 386 393
41. B. Kaplan, L.A. Shimp, N.A. Mason, F.J. Ascione Chronic hemodialysis patients. Part II: Reducing drug-related problems through application of the focused drug therapy review program Ann Pharmacother 28 1994 320 324
42. Medication use among dialysis patients in the DMMS. United States Renal Data System. Dialysis Morbidity and Mortality Study Am J Kidney Dis 32 suppl 1 1998 S60 S68
43. J.A. Koecheler, P.W. Abramowitz, S.E. Swim, C.E. Daniels Indicators for the selection of ambulatory patients who warrant pharmacist monitoring Am J Hosp Pharm 46 1989 729 732
44. B. Kaplan, N.A. Mason, L.A. Shimp, F.J. Ascione Chronic hemodialysis patients. Part I: Characterization and drug-related problems Ann Pharmacother 28 1994 316 319
45. D.J. Cleary, G.R. Matzke, A.C. Alexander, M.S. Joy Medication knowledge and compliance among patients receiving long-term dialysis Am J Health Syst Pharm 52 1995 1895 1900
46. V.A. Skoutakis, S.R. Acchiardo, D.R. Martinez, D. Lorisch, G.C. Wood Role-effectiveness of the pharmacist in the treatment of hemodialysis patients Am J Hosp Pharm 35 1978 62 65
47. I. Tang, D. Vrahnos, H. Hatoum, A. Lau Effectiveness of clinical pharmacist interventions in a hemodialysis unit Clin Ther 15 1993 459 464 discussion, 432
48. H.J. Manley, C.A. Carroll The clinical and economic impact of pharmaceutical care in end-stage renal disease patients Semin Dial 15 2002 45 49
49. C.D. Hepler The third wave in pharmaceutical education The clinical movement Am J Pharm Educ 51 1987 369 385
50. R.L. Talbert American College of Clinical Pharmacy ACCP strategic planning conference Issues and trends in clinical pharmacy education Pharmacotherapy 17 1997 1073 1078
51. T. English New schools strive to carve their own niche in pharmacy education J Am Pharm Assoc (Wash) 38 1998 304 306
52. ASHP statement on the pharmacist's role in primary care Am J Health Syst Pharm 56 1999 1665 1667
53. C.D. Hepler, L.M. Strand Opportunities and responsibilities in pharmaceutical care Am J Hosp Pharm 47 1990 533 543
54. J.D. Hayes, S.S. Sansgiry, G.K. Rice Patient satisfaction with a pharmacist-based medication assistance clinic Am J Health Syst Pharm 59 2002 2456
55. D. Epstein Can rural pharmacy survive? Drug Topics 1996 58 62
56. G.G. Weiss Hire a pharmacist? Med Econ 80 2003 23 26
57. B.L. Carter, A.J. Zillich, W.J. Elliott How pharmacists can assist physicians with controlling blood pressure J Clin Hypertens (Greenwich) 5 2003 31 37
58. L.M. Dickerson, A.M. Denham, T. Lynch The state of clinical pharmacy practice in family practice residency programs Fam Med 34 2002 653 657
59. National Kidney Foundation K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease Update 2000 Am J Kidney Dis 37 suppl 1 2001 S182 S238
60. National Kidney Foundation K/DOQ1 Clinical Practice Guidelines for Managing Dyslipidemia in Chronic Kidney Disease Am J Kidney Dis 41 suppl 3 2003 S1 S92
61. W.F. Keane, G.R. Bailie, E. Boeschoten Adult peritoneal dialysis-related peritonitis treatment recommendations 2000 Update Perit Dial Int 20 2000 396 411
62. W.L. Henrich, L.E. Agodoa, B. Barrett Analgesics and the kidney Summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation Am J Kidney Dis 27 1996 162 165
63. W.L. St Peter, G. Obrador, R.L. Roberts, A.J. Collins Trends in intravenous iron use in dialysis patients in the United States J Am Soc Nephrol 13 2002 211A (abstr)
64. J.L. Xue, W.L. St Peter, J.P. Ebben, S.E. Everson, A.J. Collins Anemia treatment in the pre-ESRD period and associated mortality in elderly patients Am J Kidney Dis 40 2002 1153 1161
65. W.W. Brown, R.M. Peters, S.E. Ohmit Early detection of kidney disease in community settings The Kidney Early Evaluation Program (KEEP) Am J Kidney Dis 42 2003 22 35
66. N.A. Mason, W.L. St Peter, C.A. Johnson, G.R. Bailie Trainees' activities and experiences after a clinical pharmacy dialysis traineeship Am J Health Syst Pharm 56 1999 1623 1626
67. G.R. Matzke, W.L. St Peter, T.J. Comstock, E.F. Foote Nephrology pharmaceutical care preceptorship A programmatic and clinical outcomes assessment Ann Pharmacother 34 2000 593 599
68. A.H. Lau, G.R. Bailie, G.R. Matzke The practice of nephrology pharmacy Results of a North American survey J Appl Ther Res 2 1999 91 100
69. W.L. St Peter According to the experts... An interview on positive clinical and financial outcomes resulting from a pharmacist-directed anemia management clinic Adv Anemia Manage 3 2004 1 2
70. K.A. Calis, L.C. Hutchison, M.E. Elliott Healthy People 2010 Challenges, opportunities, and a call to action for America's pharmacists Pharmacotherapy 24 2004 1241 1294
71. A.J. Zillich, J. Saseen, R.M. DeHart Caring for patients with chronic kidney disease A joint opinion of the Ambulatory Care and Nephrology Practice and Research Networks of the American College of Clinical Pharmacy Pharmacotherapy 25 2005 123 143
72. A.V. Chobanian, G.L. Bakris, H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure The JNC 7 report JAMA 289 2003 2560 2572
73. B.L. Carter, D.J. Barnette, E. Chrischilles, G.J. Mazzotti, Z.J. Asali Evaluation of hypertensive patients after care provided by community pharmacists in a rural setting Pharmacotherapy 17 1997 1274 1285
74. B.J. Dong, S.A. Echaves, R.V. Brody, D.W. Shapiro Pharmacist provision of preventive health care services in a hypertension clinic Am J Health Syst Pharm 54 1997 564 566
75. J.M. McKenney, J.M. Slining, H.R. Henderson, D. Devins, M. Barr The effect of clinical pharmacy services on patients with essential hypertension Circulation 48 1973 1104 1111
76. W.F. McGhan, G.L. Stimmel, T.G. Hall, T.M. Gilman A comparison of pharmacists and physicians on the quality of prescribing for ambulatory hypertensive patients Med Care 21 1983 435 444
77. J.E. Borenstein, G. Graber, E. Saltiel Physician-pharmacist comanagement of hypertension A randomized, comparative trial Pharmacotherapy 23 2003 209 216
78. D.K. Solomon, T.S. Portner, G.E. Bass Clinical and economic outcomes in the hypertension and COPD arms of a multicenter outcomes study J Am Pharm Assoc (Wash) 38 1998 574 585
79. L.A. Jaber, H. Halapy, M. Fernet, S. Tummalapalli, H. Diwakaran Evaluation of a pharmaceutical care model on diabetes management Ann Pharmacother 30 1996 238 243
80. E.A. Coast-Senior, B.A. Kroner, C.L. Kelley, L.E. Trilli Management of patients with type 2 diabetes by pharmacists in primary care clinics Ann Pharmacother 32 1998 636 641
81. P.S. Huff, T.J. Ives, S.N. Almond, N.W. Griffin Pharmacist-managed diabetes education service Am J Hosp Pharm 40 1983 991 994
82. K.W. Schilling Pharmacy program for monitoring diabetic patients Am J Hosp Pharm 34 1977 1242 1245
83. J.M. Tiggelaar Protocols for the treatment of essential hypertension and type II diabetes mellitus by pharmacists in ambulatory care clinics Drug Intell Clin Pharm 21 1987 521 529
84. C.N. Sadur, N. Moline, M. Costa Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits Diabetes Care 22 1999 2011 2017
85. Kelley KW, Ramsey LA, Rochester CD, Hood EH, Harrell TK: Management of type 2 diabetes: Comparison of a specialty clinic and an internal medicine resident clinic. ASHP Midyear Clinical Meeting. IPA vol 36, pp P554E, 2001
86. M.C. Shibley, C.B. Pugh Implementation of pharmaceutical care services for patients with hyperlipidemias by independent community pharmacy practitioners Ann Pharmacother 31 1997 713 719
87. R.T. Tsuyuki, J.A. Johnson, K.K. Teo A randomized trial of the effect of community pharmacist intervention on cholesterol risk management The Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP) Arch Intern Med 162 2002 1149 1155
88. S.L. Ellis, B.L. Carter, D.C. Malone Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: The IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers Pharmacotherapy 20 2000 1508 1516
89. M. Bozovich, C.M. Rubino, J. Edmunds Effect of a clinical pharmacist-managed lipid clinic on achieving National Cholesterol Education Program low-density lipoprotein goals Pharmacotherapy 20 2000 1375 1383
90. W.M. Awni, J. Yeh, C.E. Halstenson Effect of haemodialysis on the pharmacokinetics of cetirizine Eur J Clin Pharmacol 38 1990 67 69
91. B.G. Blackwell, J.E. Leggett, C.A. Johnson, S.W. Zimmerman, W.A. Craig Ampicillin and sulbactam pharmacokinetics and pharmacodynamics in continuous ambulatory peritoneal dialysis (CAPD) Perit Dial Int 10 1990 221 226
92. T.W. Gehr, D.W. Rudy, G.R. Matzke The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency Clin Pharmacol Ther 56 1994 31 38
93. C.E. Halstenson, C.A. Hirata, K.L. Heim-Duthoy, P.A. Abraham, G.R. Matzke Effect of concomitant administration of piperacillin on the dispositions of netilmicin and tobramycin in patients with end-stage renal disease Antimicrob Agents Chemother 34 1990 128 133
94. C.A. Johnson, A. Ateshkadi, S.W. Zimmerman Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis Antimicrob Agents Chemother 37 1993 2650 2655
95. S.F. Kowalsky, M. Echols, M.T. Schwartz, G.R. Bailie, E. McCormick Pharmacokinetics of ciprofloxacin in subjects with varying degrees of renal function and undergoing hemodialysis or CAPD Clin Nephrol 39 1993 53 58
96. A.H. Lau, K. Pyle, N.O. Kronfol, C.R. Libertin Removal of cephalosporins by continuous arteriovenous ultrafiltration (CAVU) and hemofiltration (CAVH) Int J Artif Organs 12 1989 379 383
97. G.R. Matzke, C.E. Halstenson, J.A. Opsahl Pharmacokinetics of loratadine in patients with renal insufficiency J Clin Pharmacol 30 1990 364 371
98. S.L. Preston, L.L. Briceland, B.M. Lomaestro Dosing adjustment of 10 antimicrobials for patients with renal impairment Ann Pharmacother 29 1995 1202 1207
99. W.L. St Peter, K.A. Redic-Kill, C.E. Halstenson Clinical pharmacokinetics of antibiotics in patients with impaired renal function Clin Pharmacokinet 22 1992 169 210
100. D.F. Brophy, L.D. Wazny, T.W. Gehr, T.J. Comstock, J. Venitz The pharmacokinetics of subcutaneous enoxaparin in end-stage renal disease Pharmacotherapy 21 2001 169 174
101. E.F. Foote, W.B. Dreitlein, C.A. Steward Pharmacokinetics of vancomycin when administered during high flux hemodialysis Clin Nephrol 50 1998 51 55
102. D.W. Grabe, G.R. Bailie, G. Eisele, R.F. Frye Pharmacokinetics of intermittent intraperitoneal ceftazidime Am J Kidney Dis 33 1999 111 117
103. M.S. Joy, G.R. Matzke, R.F. Frye, P.M. Palevsky Determinants of vancomycin clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis Am J Kidney Dis 31 1998 1019 1027
104. C.A. Knupp, L.J. Hak, D.F. Coakley Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure Influence of hemodialysis and continuous ambulatory peritoneal dialysis Clin Pharmacol Ther 60 1996 535 542
105. C.L. Low, G.R. Bailie, A. Evans, G. Eisele, R.A. Venezia Pharmacokinetics of once-daily IP gentamicin in CAPD patients Perit Dial Int 16 1996 379 384
106. R.S. Malone, D.N. Fish, E. Abraham, I. Teitelbaum Pharmacokinetics of levofloxacin and ciprofloxacin during continuous renal replacement therapy in critically ill patients Antimicrob Agents Chemother 45 2001 2949 2954
107. R.S. Malone, D.N. Fish, D.M. Spiegel, J.M. Childs, C.A. Peloquin The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol Am J Respir Crit Care Med 159 1999 1580 1584
108. H.J. Manley, G.R. Bailie, R. Frye, M.D. McGoldrick Intermittent intravenous piperacillin pharmacokinetics in automated peritoneal dialysis patients Perit Dial Int 20 2000 686 693
109. H.J. Manley, G.R. Bailie, R. Frye, L.D. Hess, M.D. McGoldrick Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis J Am Soc Nephrol 11 2000 1310 1316
110. M.A. Marx, R.F. Frye, G.R. Matzke, T.A. Golper Cefazolin as empiric therapy in hemodialysis-related infections Efficacy and blood concentrations Am J Kidney Dis 32 1998 410 414
111. G.R. Matzke, R.F. Frye, M.S. Joy, P.M. Palevsky Determinants of ceftriaxone clearance by continuous venovenous hemofiltration and hemodialysis Pharmacotherapy 20 2000 635 643
112. G.R. Matzke, R.F. Frye, M.S. Joy, P.M. Palevsky Determinants of ceftazidime clearance by continuous venovenous hemofiltration and continuous venovenous hemodialysis Antimicrob Agents Chemother 44 2000 1639 1644
113. A.A. Pedro, T.W. Gehr, D.F. Brophy, D.A. Sica The pharmacokinetics and pharmacodynamics of losartan in continuous ambulatory peritoneal dialysis J Clin Pharmacol 40 2000 389 395
114. L.K. Golightly, C.L. O'Fallon, W.D. Moran, A.H. Sorocki Pharmacist monitoring of drug therapy in patients with abnormal serum creatinine levels Hosp Pharm 28 1993 725 727 730-722
115. D.S. Silverberg, D. Wexler, M. Blum Effect of correction of anemia with erythropoietin and intravenous iron in resistant heart failure in octogenarians Isr Med Assoc J 5 2003 337 339
116. S. Kuriyama, H. Tomonari, H. Yoshida Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients Nephron 77 1997 176 185
117. A. Ateshkadi, C.A. Johnson, L.L. Oxton Pharmacokinetics of intraperitoneal, intravenous, and subcutaneous recombinant human erythropoietin in patients on continuous ambulatory peritoneal dialysis Am J Kidney Dis 21 1993 635 642
118. L.L. To, C.P. Stoner, S.N. Stolley, J.D. Buenviaje, T.W. Ziegler Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit Am J Health Syst Pharm 58 2001 2061 2065
119. G.R. Bailie, R. Hamilton, G. Eisele Evaluation of an erythropoietin dosing nomogram in CAPD patients Int J Pharm Pract 1 1992 164 166
120. Ueoka J, DiBaernardo NA, Calescibetta CC, Hill TR: Pharmacist-managed subcutaneous erythropoietin dose adjustment program in an outpatient hemodialysis unit. ASHP Midyear Clinical Meeting. IPA vol 35, pp MCS-34, 2000
121. Qin M, Patel PB, Bach DS: Impact of pharmacy services in the end stage renal disease patient. ASPH Midyear Clinical Meeting. IPA vol 33, pp P-387E, 1998
122. G.R. Matzke, T.J. Comstock, S.J. Coons Hospital Pharmacy Cooperative Study Group A randomized controlled trial of clinical pharmacists' interventions vs standard care for anemia management in hemodialysis patients J Am Soc Nephrol 10 1999 264A (abstr)
123. J.Q. Hudson, M.S. Joy, M.K. Stamatakis, T. Walton, G. Miller, C. Smith Nephrology practice and research network surveillance study Anemia management in dialysis patients Pharmacotherapy 22 2002 414
124. M.S. Joy, K. Dornbrook-Lavender, A. Mottl, R.F. Falk Clinical and economic outcomes associated with a chronic kidney disease clinic Pharmacotherapy 23 2003 1371A (abstr)
125. M.S. Joy, K. Dornbrook-Lavender, A. Mottl, B.V. Vaillancort, R.F. Falk A multidisciplinary approach to anemia management J Am Soc Nephrol 14 2003 790A (abstr)
126. M.S. Joy, K. Dornbrook-Lavender, A. Mottl, B.V. Vaillancort, R.F. Falk Anemia treatment outcomes in a chronic kidney disease (CKD) clinic J Am Soc Nephrol 14 2003 789A (abstr)
127. C.A. Johnson, E. Rosowski, S.W. Zimmerman A prospective open-label study evaluating the efficacy and adverse reactions of the use of Niferex-150 in ESRD patients receiving Epogen Adv Perit Dial 8 1992 444 447
128. W.L. St Peter, L.J. Lambrecht, M. Macres Randomized cross-over study of adverse reactions and cost implications of intravenous push compared with infusion of iron dextran in hemodialysis patients Am J Kidney Dis 28 1996 523 528
129. P.S. Driver Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood Am J Health Syst Pharm 55 suppl 4 1998 S12 S16
130. R. London, A. Solis, G.A. Goldberg, S. Wade, S. Ryu Health care resource utilization and the impact of anemia management in patients with chronic kidney disease Am J Kidney Dis 40 2002 539 548
131. J.W. Coburn, H.M. Maung Use of active vitamin D sterols in patients with chronic kidney disease, stages 3 and 4 Kidney Int Suppl 85 2003 S49 S53
132. Anonymous Pharmacist-run program optimally manages secondary hyperparathyroidism Formulary 33 1998 1217 1218
133. M.K. Stamatakis, J.Q. Hudson, M.S. Joy, T. Walton, G. Miller, C. Smith Treatment of hyperphosphatemia and secondary hyperparathyroidism in patients undergoing dialysis Results from the nephrology drug surveillance network Pharmacotherapy 22 2002 414A 415A (abstr)
134. M.S. Joy, N. Franceschini, R.J. Falk Elevated parathyroid hormone and 25-vitamin D deficiency is present in stages 3, 4, and 5 chronic kidney disease (CKD) J Am Soc Nephrol 15 2004 732A (abstr)
135. M.S. Joy, W.F. Finn Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate A new phosphate binder for the treatment of hyperphosphatemia Am J Kidney Dis 42 2003 96 107
136. W.F. Finn, M.S. Joy, G. Hladik Lanthanum Study Group Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis Clin Nephrol 62 2004 193 201
137. D.F. Brophy, J.F. Wallace, D.T. Kennedy, T.W. Gehr, D.A. Holdford Cost-effectiveness of sevelamer hydrochloride versus calcium carbonate + atorvastatin for LDL cholesterol reduction in chronic renal insufficiency patients with dyslipidemia and hyperphosphatemia Pharmacotherapy 20 2000 950 957
138. A.J. Collin, W.L. St Peter, F.W. Dalleska, J.P. Ebben, J.Z. Ma Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients Clin Nephrol 54 2000 334 341
139. D.W. Grabe, G.R. Bailie, G. Eisele, C.L. Low Hemodialysis patients' knowledge of their phosphate binder therapy J Appl Ther Res 2 1992 125 132
140. M.S. Joy, K.D. Hollar, C.D. Neyhart Assessment of risk factors for bone disease in renal transplant recipients J Pharm Pract 18 2002 54 62
141. M.S. Joy, C.D. Neyhart, M.A. Dooley A multidisciplinary renal clinic for corticosteroid-induced bone disease Pharmacotherapy 20 2000 206 216
142. T. Wong, E.F. Foote, G.S. Lefavour Physician knowledge and practice patterns relating to diabetic nephropathy J Am Pharm Assoc (Wash) 39 1999 785 790
143. W. Paris, S. Dunham, A. Sebastian, C. Jacobs, B. Nour Medication nonadherence and its relation to financial restriction J Transplant Coord 9 1999 149 152
144. C.J. Lowe, D.K. Raynor, J. Purvis, A. Farrin, J. Hudson Effects of a medicine review and education programme for older people in general practice Br J Clin Pharmacol 50 2000 172 175
145. S.L. Williford, D.F. Johnson Impact of pharmacist counseling on medication knowledge and compliance Mil Med 160 1995 561 564
146. S. Weiner, J. Dischler, C. Horvitz Beyond pharmaceutical manufacturer assistance Broadening the scope of an indigent drug program Am J Health Syst Pharm 58 2001 146 150